CN107427500A - 治疗copd和其它炎症性病况的组合物和方法 - Google Patents

治疗copd和其它炎症性病况的组合物和方法 Download PDF

Info

Publication number
CN107427500A
CN107427500A CN201680016932.2A CN201680016932A CN107427500A CN 107427500 A CN107427500 A CN 107427500A CN 201680016932 A CN201680016932 A CN 201680016932A CN 107427500 A CN107427500 A CN 107427500A
Authority
CN
China
Prior art keywords
pde4b2
activating agent
expression
pka
roflumilast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680016932.2A
Other languages
English (en)
Chinese (zh)
Inventor
李建东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia State University Research Foundation Inc
Original Assignee
Georgia State University Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia State University Research Foundation Inc filed Critical Georgia State University Research Foundation Inc
Publication of CN107427500A publication Critical patent/CN107427500A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680016932.2A 2015-03-20 2016-03-21 治疗copd和其它炎症性病况的组合物和方法 Pending CN107427500A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136115P 2015-03-20 2015-03-20
US62/136,115 2015-03-20
PCT/US2016/023475 WO2016154143A1 (en) 2015-03-20 2016-03-21 Compositions and methods for treating copd and other inflammatory conditions

Publications (1)

Publication Number Publication Date
CN107427500A true CN107427500A (zh) 2017-12-01

Family

ID=56979181

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680016932.2A Pending CN107427500A (zh) 2015-03-20 2016-03-21 治疗copd和其它炎症性病况的组合物和方法

Country Status (6)

Country Link
US (1) US11045456B2 (enExample)
EP (1) EP3270921A4 (enExample)
JP (1) JP6960855B2 (enExample)
CN (1) CN107427500A (enExample)
HK (1) HK1247123A1 (enExample)
WO (1) WO2016154143A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202002321YA (en) * 2017-09-27 2020-04-29 Univ Southern California Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051474A1 (en) * 2006-10-19 2008-05-02 The Uab Research Foundation Water soluble curcumin-based compounds
CN102300568A (zh) * 2008-12-05 2011-12-28 赢泰医药科技发展有限公司 Hif-1蛋白积聚的抑制剂
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
CN104379180A (zh) * 2012-04-10 2015-02-25 佐治亚州立大学研究基金会公司 用cyld抑制剂治疗中耳炎及其它病状的组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536738A1 (en) * 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
WO2008070616A2 (en) * 2006-12-01 2008-06-12 University Of Utah Research Foundation METHODS AND COMPOSITIONS RELATED TO HIF-1α

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051474A1 (en) * 2006-10-19 2008-05-02 The Uab Research Foundation Water soluble curcumin-based compounds
CN102300568A (zh) * 2008-12-05 2011-12-28 赢泰医药科技发展有限公司 Hif-1蛋白积聚的抑制剂
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
CN104379180A (zh) * 2012-04-10 2015-02-25 佐治亚州立大学研究基金会公司 用cyld抑制剂治疗中耳炎及其它病状的组合物和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BORA ET AL: "A reporter gene assay for screening of PDE4 subtype selective inhibitors", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 *
CULLEN ET AL: "investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
WO2016154143A1 (en) 2016-09-29
US20180042904A1 (en) 2018-02-15
WO2016154143A8 (en) 2017-09-28
EP3270921A1 (en) 2018-01-24
US11045456B2 (en) 2021-06-29
JP6960855B2 (ja) 2021-11-05
HK1247123A1 (zh) 2018-09-21
JP2018510153A (ja) 2018-04-12
EP3270921A4 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
JP7728402B2 (ja) 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法
US8007790B2 (en) Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US20110059949A1 (en) Prophylaxis and treatment of infectious diseases
CN103096978A (zh) 方法
JP2023533485A (ja) 重症型の肺高血圧症の治療方法
US20120294956A1 (en) Inhibition of dynamin related protein 1 to promote cell death
CN114712503B (zh) c-Abl抑制剂在制备预防和/或治疗肌萎缩性侧索硬化症药物中的应用
CN115998872B (zh) 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途
JP2021535152A (ja) 神経変性障害を処置するためのｒｉｐキナーゼの阻害法
JP2025081323A (ja) ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
US9951335B2 (en) Compositions and methods for treating otitis media and other conditions with inhibitors of CYLD
KR20090021163A (ko) Ｈｃｖ 감염증을 치료 또는 예방하기 위한 의약 조성물
CN1980681A (zh) GSK－3β的调节及治疗增殖性病变的方法
US10660957B2 (en) Compositions and methods for treating an Aβ-modulated disease or disorder or improving cognition in a subject
US11045456B2 (en) Compositions and methods for treating COPD and other inflammatory conditions
JP2023507816A (ja) がんを治療するための方法及び組成物
US20190365745A1 (en) Use of chronic treatment with atr inhibitors to sensitize cancer cells to parp inhibitors
Zhang et al. STING-mediated neuroinflammation: A therapeutic target in neurodegenerative diseases
JP2006528225A (ja) 糖尿病処置のためのチロシンキナーゼ阻害剤の使用
Maïga Exploiting eIF4F-Dependent Translational Control as a Therapeutic Target in Disease
EP4611728A1 (en) Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
Itoua Maïga Exploiting eIF4F-Dependent Translational Control as a Therapeutic Target in Disease
WO2025059029A1 (en) Methods of treating vexas syndrome
CN117959442A (zh) 预防或治疗肺纤维化的试剂及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1247123

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1247123

Country of ref document: HK